MCID: ORL007
MIFTS: 61

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Neoplasm of Floor of Mouth 12
Malignant Tumor of Floor of Mouth 6
Neoplasm of the Oral Cavity 29
Malignant Neoplasm of Mouth 73
Oral Cavity Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8618
NCIt 50 C9318

Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to leukoplakia and lip and oral cavity cancer. An important gene associated with Oral Cavity Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and testes, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 30.4 CYP1A1 GSTM1 GSTT1
2 lip and oral cavity cancer 12.5
3 oral squamous cell carcinoma 11.1
4 salivary gland carcinoma 11.1
5 breast intraductal proliferative lesion 10.4 EGFR ERBB2
6 geographic tongue 10.4 EGFR TNFRSF10B VEGFA
7 colorectal cancer, childhood 10.4 CYP1A1 GSTM1
8 primary peritoneal carcinoma 10.4 EGFR ERBB2 VEGFA
9 breast carcinoma in situ 10.3 EGFR ERBB2 VEGFA
10 sister chromatid exchange, frequency of 10.3 ALDH2 GSTM1 GSTT1
11 laryngeal disease 10.3 EGFR GSTM1 GSTT1
12 oral submucous fibrosis 10.3 CYP1A1 GSTM1 GSTT1
13 pharynx cancer 10.3 EGFR GSTM1 VEGFA
14 esophageal disease 10.3 ALDH2 EGFR ERBB2
15 oral cancer 10.3 CYP1A1 EGFR GSTM1 GSTT1
16 nervous system cancer 10.3 EGFR PTEN VEGFA
17 bladder disease 10.3 ERBB2 GSTM1 GSTT1
18 hearing loss, noise-induced 10.3 GSTM1 GSTT1
19 stomach disease 10.3 EGFR ERBB2 VEGFA
20 laryngeal squamous cell carcinoma 10.3 EGFR GSTT1 VEGFA
21 breast squamous cell carcinoma 10.3 EGFR ERBB2 PIK3CA
22 breast disease 10.3 BAX CYP1A1 ERBB2 VEGFA
23 adenosquamous lung carcinoma 10.3 EGFR ERBB2 PIK3CA
24 acneiform dermatitis 10.3 CYP1A1 EGFR ERBB2 PIK3CA
25 supratentorial cancer 10.3 EGFR PTEN SOX2 VEGFA
26 cerebrum cancer 10.3 EGFR PTEN SOX2 VEGFA
27 ovarian cancer 1 10.3 ERBB2 PIK3CA VEGFA
28 malignant ovarian surface epithelial-stromal neoplasm 10.3 ERBB2 PIK3CA VEGFA
29 central nervous system cancer 10.3 EGFR PTEN SOX2 VEGFA
30 ovary epithelial cancer 10.3 ERBB2 PIK3CA VEGFA
31 female reproductive system disease 10.3 EGFR ERBB2 PTEN VEGFA
32 mucinous stomach adenocarcinoma 10.3 PTEN VEGFA
33 reproductive system disease 10.3 EGFR ERBB2 PTEN VEGFA
34 endometrial adenocarcinoma 10.3 EGFR ERBB2 PTEN VEGFA
35 serous cystadenocarcinoma 10.3 ERBB2 PIK3CA VEGFA
36 ovary adenocarcinoma 10.3 BAX ERBB2 PIK3CA
37 cystadenocarcinoma 10.3 ERBB2 PIK3CA VEGFA
38 estrogen-receptor positive breast cancer 10.3 EGFR ERBB2 PIK3CA
39 grade iii astrocytoma 10.3 EGFR PTEN VEGFA
40 endocrine gland cancer 10.3 EGFR ERBB2 PTEN VEGFA
41 adult hepatocellular carcinoma 10.3 CASP8 PIK3CA
42 pancreas adenocarcinoma 10.3 EGFR ERBB2 PIK3CA VEGFA
43 larynx cancer 10.2 EGFR GSTM1 GSTT1 PTEN
44 acute t cell leukemia 10.2 BAX CASP8 PTEN
45 acute lymphocytic leukemia 10.2 GSTM1 GSTT1 MCL1
46 thyroid hurthle cell adenoma 10.2 PIK3CA PTEN
47 carcinosarcoma 10.2 ERBB2 PIK3CA PTEN
48 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2
49 ovarian serous cystadenocarcinoma 10.2 BAX ERBB2 PIK3CA
50 uterine anomalies 10.2 ERBB2 PIK3CA PTEN VEGFA

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 EGFR ERBB2 GSTM1 PTEN VEGFA
2 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
3 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 ALDH2 BAX CASP8 CYP1A1 EGFR ERBB2
2 cardiovascular system MP:0005385 10.41 ALDH2 CASP8 CYP1A1 EGFR ERBB2 FADD
3 cellular MP:0005384 10.4 ALDH2 BAX CASP8 EGFR ERBB2 FADD
4 endocrine/exocrine gland MP:0005379 10.38 ALDH2 BAX CASP8 CYP1A1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.38 ALDH2 BAX CASP8 CYP1A1 EGFR ERBB2
6 mortality/aging MP:0010768 10.38 ALDH2 BAX CASP8 CYP1A1 EGFR ERBB2
7 immune system MP:0005387 10.34 ALDH2 BAX CASP8 CYP1A1 EGFR FADD
8 hematopoietic system MP:0005397 10.33 ALDH2 BAX CASP8 CYP1A1 EGFR FADD
9 embryo MP:0005380 10.32 CASP8 EGFR ERBB2 FADD HSP90B1 LIN28B
10 muscle MP:0005369 10.23 ALDH2 BAX CASP8 EGFR ERBB2 FADD
11 nervous system MP:0003631 10.22 ALDH2 BAX CASP8 EGFR ERBB2 FADD
12 integument MP:0010771 10.21 ALDH2 CASP8 EGFR ERBB2 MCL1 PIK3CA
13 liver/biliary system MP:0005370 10.15 ALDH2 CASP8 CYP1A1 EGFR FADD GDF15
14 digestive/alimentary MP:0005381 10.13 EGFR ERBB2 FADD PTEN SOX2 TLR2
15 neoplasm MP:0002006 10.13 ALDH2 BAX CASP8 EGFR ERBB2 PIK3CA
16 normal MP:0002873 9.97 CYP1A1 EGFR ERBB2 LIN28B MCL1 PTEN
17 no phenotypic analysis MP:0003012 9.91 CYP1A1 EGFR FADD HSP90B1 PIK3CA SOX2
18 renal/urinary system MP:0005367 9.86 ALDH2 BAX CASP8 EGFR GDF15 PTEN
19 reproductive system MP:0005389 9.81 ALDH2 BAX EGFR ERBB2 MCL1 PIK3CA
20 respiratory system MP:0005388 9.56 BAX CASP8 EGFR ERBB2 PTEN SOX2
21 skeleton MP:0005390 9.32 ALDH2 BAX EGFR ERBB2 FADD PIK3CA

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
3
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
4
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
5
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
6
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
7
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
8
Pentetic acid Approved Phase 4 67-43-6
9
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
10
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
11
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
12 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1,Not Applicable
13 Adrenergic beta-Agonists Phase 4,Phase 2,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Sympathomimetics Phase 4,Phase 2,Not Applicable
16 Epinephryl borate Phase 4,Phase 2,Phase 1
17 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
18 Mydriatics Phase 4,Phase 2
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
21 Respiratory System Agents Phase 4,Phase 2,Not Applicable
22 Anti-Asthmatic Agents Phase 4,Phase 2
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Bronchodilator Agents Phase 4,Phase 2
27 Anticoagulants Phase 4,Not Applicable
28 Radiopharmaceuticals Phase 4,Phase 1,Phase 2,Not Applicable
29 Chelating Agents Phase 4,Not Applicable,Early Phase 1
30 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
32 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
33
protease inhibitors Phase 4,Phase 2,Phase 3
34 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Vasodilator Agents Phase 4,Not Applicable
36 Dopamine agonists Phase 4
37 Cardiotonic Agents Phase 4,Not Applicable
38 Dopamine Agents Phase 4,Phase 2
39 Blood Substitutes Phase 4
40 Technetium Tc 99m Sulfur Colloid Phase 4,Not Applicable
41 Technetium Tc 99m Pentetate Phase 4
42 Dextrans Phase 4
43 Plasma Substitutes Phase 4
44 Antidepressive Agents Phase 4,Phase 3,Phase 2
45 Antidepressive Agents, Second-Generation Phase 4,Phase 2
46 Dopamine Uptake Inhibitors Phase 4,Phase 2
47 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
48 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
49 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
50 Nicotinic Agonists Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
2 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
7 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
8 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Recruiting NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
9 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
10 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
11 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
12 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
13 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
14 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
15 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
16 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
17 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
18 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
19 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
20 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
21 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
22 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
23 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
24 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
25 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
26 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
27 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
28 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
29 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
30 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
31 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
32 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
33 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
36 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
37 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
38 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
39 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
40 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
41 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
42 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
43 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
44 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
45 Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
46 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
47 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Recruiting NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
48 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
49 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
50 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Genetic tests related to Oral Cavity Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Oral Cavity 29

Anatomical Context for Oral Cavity Cancer

MalaCards organs/tissues related to Oral Cavity Cancer:

41
Lymph Node, Lung, Testes, Tongue, Bone, Eye, Salivary Gland

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The Oral Cavity

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 325)
# Title Authors Year
1
Comparison of psychosocial factors over time among HPV+ oropharyngeal cancer and tobacco-related oral cavity cancer patients. ( 30322742 )
2019
2
Oral Cavity Cancer. ( 30454788 )
2019
3
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. ( 29706184 )
2018
4
Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. ( 29313448 )
2018
5
Detection of surgical margins in oral cavity cancer: the role of dynamic optical contrast imaging. ( 29517537 )
2018
6
Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. ( 29761306 )
2018
7
Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins? ( 29790687 )
2018
8
Locoregionally advanced oral cavity cancer: A propensity-score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. ( 29665118 )
2018
9
The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. ( 29655817 )
2018
10
MR lymphography for sentinel lymph node detection in patients with oral cavity cancer: Preliminary clinical study. ( 29633413 )
2018
11
The influence of marital status on survival for patients aged 65 years and younger with oral cavity cancer. ( 29685504 )
2018
12
The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )
2018
13
Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. ( 29546525 )
2018
14
Opioid prescribing practices in patients undergoing surgery for oral cavity cancer. ( 29756393 )
2018
15
Genetic analysis of surgical margins in oral cavity cancer. ( 29341160 )
2018
16
Narrow Band Imaging-guided resection of oral cavity cancer decreases local recurrence and increases survival. ( 29480612 )
2018
17
Aberrant DNA methylation of the <i>p16, APC, MGMT, TIMP3</i> and <i>CDH1</i> gene promoters in tumours and the surgical margins of patients with oral cavity cancer. ( 29896273 )
2018
18
Diagnostic Pathway of Oral Cavity Cancer in an Integrated Health Care System. ( 29616906 )
2018
19
Can MR textural analysis improve the prediction of extracapsular nodal spread in patients with oral cavity cancer? ( 29872911 )
2018
20
Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29739969 )
2018
21
Complete atrioventricular block as an initial manifestation of recurred oral cavity cancer: a case report. ( 29986652 )
2018
22
Combination of recurrent oral aphthae and dry eye syndrome may constitute an independent risk factor for oral cavity cancer in elderly women. ( 30233243 )
2018
23
Swallowing ability and its impact on dysphagia-specific health-related QOL in oral cavity cancer patients post-treatment. ( 30322515 )
2018
24
High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands. ( 29575685 )
2018
25
Author Correction: Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29991743 )
2018
26
Diagnostic pathway of oral cavity cancer in an integrated health care system. ( 30095106 )
2018
27
Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. ( 30220313 )
2018
28
Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. ( 30284248 )
2018
29
Toward complete oral cavity cancer resection using a handheld diffuse reflectance spectroscopy probe. ( 30341837 )
2018
30
Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution. ( 30349385 )
2018
31
Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. ( 30408182 )
2018
32
Evaluation of early oral cavity cancer treatment quality at a single institution. ( 30408196 )
2018
33
Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. ( 30452499 )
2018
34
Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. ( 28865100 )
2017
35
Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. ( 28880746 )
2017
36
Recent Trends in Oral Cavity Cancer Research Support in the United States. ( 28033064 )
2017
37
Comparison of facility type outcomes for oral cavity cancer: Analysis of the national cancer database. ( 28671267 )
2017
38
Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. ( 28426848 )
2017
39
Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. ( 28806994 )
2017
40
Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. ( 29257122 )
2017
41
Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. ( 28797467 )
2017
42
Treatment outcome of advance staged oral cavity cancer: concurrent chemoradiotherapy compared with primary surgery. ( 28321535 )
2017
43
What additional treatment is indicated for oral cavity cancer with isolated perineural invasion? ( 28349551 )
2017
44
Estimating Survival After Salvage Surgery for Recurrent Oral Cavity Cancer. ( 28448645 )
2017
45
Factors associated with continued smoking after treatment of oral cavity cancer: An age and survival time-matched study. ( 29148210 )
2017
46
Frequency of Depression and its Correlation with Quality of Life of Patients with Oral Cavity Cancer. ( 28883770 )
2017
47
Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. ( 28838425 )
2017
48
Chronic Opioid Use Following Surgery for Oral Cavity Cancer. ( 28445584 )
2017
49
Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer. ( 28645807 )
2017
50
Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. ( 29256326 )
2017

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
2 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
3 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
4 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
5 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh37 Chromosome 3, 178952090: 178952090
6 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh38 Chromosome 3, 179234302: 179234302

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CASP8 EGFR ERBB2 FADD HSP90B1 MCL1
2
Show member pathways
13.88 BAX CASP8 EGFR ERBB2 FADD GDF15
3
Show member pathways
13.41 BAX EGFR ERBB2 FADD GDF15 PTEN
4
Show member pathways
13.38 EGFR ERBB2 HSP90B1 MCL1 PIK3CA SOX2
5
Show member pathways
13.31 BAX CASP8 EGFR ERBB2 GDF15 PTEN
6
Show member pathways
13 BAX CASP8 EGFR FADD PIK3CA PTEN
7
Show member pathways
12.92 BAX CASP8 EGFR FADD PIK3CA PTEN
8
Show member pathways
12.91 EGFR ERBB2 PIK3CA PTEN VEGFA
9
Show member pathways
12.85 BAX EGFR ERBB2 HSP90B1 PIK3CA PTEN
10
Show member pathways
12.81 BAX CASP8 FADD MCL1 PIK3CA TNFRSF10B
11
Show member pathways
12.8 CASP8 FADD PIK3CA TLR2 TNFRSF10B
12
Show member pathways
12.77 BAX EGFR ERBB2 PIK3CA PTEN VEGFA
13
Show member pathways
12.74 BAX CASP8 EGFR ERBB2 FADD HSP90B1
14
Show member pathways
12.71 BAX EGFR ERBB2 GSTM1 GSTT1 PIK3CA
15
Show member pathways
12.61 CASP8 FADD PIK3CA TLR2 TNFRSF10B VEGFA
16
Show member pathways
12.59 CASP8 EGFR FADD PIK3CA PTEN TNFRSF10B
17
Show member pathways
12.5 EGFR ERBB2 PIK3CA PTEN
18 12.5 EGFR ERBB2 MCL1 PIK3CA PTEN VEGFA
19
Show member pathways
12.49 BAX ERBB2 PIK3CA PTEN
20
Show member pathways
12.48 EGFR ERBB2 PIK3CA VEGFA
21
Show member pathways
12.44 BAX CASP8 EGFR ERBB2 PIK3CA
22
Show member pathways
12.41 BAX HSP90B1 PIK3CA PTEN
23
Show member pathways
12.39 BAX CASP8 PTEN TNFRSF10B
24
Show member pathways
12.34 CASP8 FADD HSP90B1 TLR2
25
Show member pathways
12.31 CASP8 FADD PIK3CA TNFRSF10B
26 12.29 BAX CASP8 FADD PIK3CA TLR2
27 12.28 EGFR ERBB2 PIK3CA TLR2 VEGFA
28
Show member pathways
12.27 BAX CASP8 PTEN TNFRSF10B
29 12.25 BAX CASP8 FADD TLR2
30
Show member pathways
12.23 BAX CASP8 FADD TNFRSF10B
31 12.2 BAX EGFR TLR2 VEGFA
32
Show member pathways
12.15 EGFR ERBB2 PIK3CA PTEN
33 12.15 BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
34
Show member pathways
12.14 BAX EGFR ERBB2 HSP90B1 PIK3CA PTEN
35
Show member pathways
12.12 EGFR ERBB2 PIK3CA PTEN
36
Show member pathways
12.1 BAX EGFR GDF15 PIK3CA TNFRSF10B
37 12.08 BAX CASP8 EGFR ERBB2 FADD GSTM1
38 12.07 BAX EGFR ERBB2 HSP90B1 PIK3CA PTEN
39 12.06 GSTM1 GSTT1 HSP90B1 PIK3CA VEGFA
40 12.03 BAX CASP8 EGFR FADD PTEN VEGFA
41 12 BAX ERBB2 PIK3CA PTEN
42 11.99 HSP90B1 MCL1 SOX2 VEGFA
43 11.92 BAX EGFR GDF15 MCL1 PTEN TNFRSF10B
44 11.91 BAX PIK3CA VEGFA
45 11.91 EGFR ERBB2 PIK3CA VEGFA
46 11.88 BAX PIK3CA PTEN
47
Show member pathways
11.88 EGFR ERBB2 VEGFA
48
Show member pathways
11.84 HSP90B1 MCL1 PIK3CA
49
Show member pathways
11.83 CASP8 EGFR ERBB2 HSP90B1 PIK3CA TLR2
50
Show member pathways
11.82 BAX CASP8 FADD MCL1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.67 CASP8 EGFR FADD TLR2
2 cell body GO:0044297 9.58 CASP8 FADD TLR2
3 cytoplasm GO:0005737 9.53 BAX CASP8 CYP1A1 EGFR ERBB2 FADD
4 death-inducing signaling complex GO:0031264 9.32 CASP8 FADD
5 Bcl-2 family protein complex GO:0097136 9.26 BAX MCL1
6 CD95 death-inducing signaling complex GO:0031265 9.16 CASP8 FADD
7 ripoptosome GO:0097342 8.96 CASP8 FADD

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 BAX CYP1A1 EGFR ERBB2 PTEN
2 apoptotic process GO:0006915 9.91 BAX CASP8 FADD MCL1 PTEN TLR2
3 cytokine-mediated signaling pathway GO:0019221 9.89 HSP90B1 MCL1 PIK3CA SOX2 VEGFA
4 response to hypoxia GO:0001666 9.88 CYP1A1 HSP90B1 TLR2 VEGFA
5 positive regulation of protein kinase B signaling GO:0051897 9.87 EGFR ERBB2 GDF15 PIK3CA
6 cell surface receptor signaling pathway GO:0007166 9.85 CASP8 EGFR ERBB2 FADD TNFRSF10B
7 response to toxic substance GO:0009636 9.84 BAX CYP1A1 TLR2
8 positive regulation of MAPK cascade GO:0043410 9.83 EGFR ERBB2 GDF15 SOX2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 EGFR PIK3CA VEGFA
10 liver development GO:0001889 9.81 CYP1A1 EGFR PIK3CA
11 response to wounding GO:0009611 9.8 BAX CYP1A1 SOX2
12 apoptotic signaling pathway GO:0097190 9.79 BAX CASP8 FADD
13 positive regulation of epithelial cell proliferation GO:0050679 9.79 EGFR ERBB2 VEGFA
14 positive regulation of MAP kinase activity GO:0043406 9.78 EGFR ERBB2 VEGFA
15 extrinsic apoptotic signaling pathway GO:0097191 9.73 BAX CASP8 FADD
16 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.71 BAX CASP8 FADD TNFRSF10B
17 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.69 CASP8 FADD TNFRSF10B
18 negative regulation of phagocytosis GO:0050765 9.67 PTEN TLR2
19 activation of cysteine-type endopeptidase activity GO:0097202 9.66 CASP8 FADD
20 positive regulation of macrophage differentiation GO:0045651 9.65 CASP8 FADD
21 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.65 BAX SOX2
22 response to arsenic-containing substance GO:0046685 9.65 CYP1A1 PTEN
23 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.65 BAX FADD MCL1
24 toll-like receptor 3 signaling pathway GO:0034138 9.63 CASP8 FADD
25 regulation of apoptotic process GO:0042981 9.63 BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
26 death-inducing signaling complex assembly GO:0071550 9.62 CASP8 FADD
27 cellular response to mechanical stimulus GO:0071260 9.62 CASP8 EGFR FADD TNFRSF10B
28 ERBB2 signaling pathway GO:0038128 9.61 EGFR ERBB2 PIK3CA
29 regulation of necroptotic process GO:0060544 9.6 CASP8 FADD
30 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGFR ERBB2
31 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.55 BAX CASP8
32 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.43 CASP8 FADD TNFRSF10B
33 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.26 BAX CASP8 FADD TNFRSF10B
34 TRAIL-activated apoptotic signaling pathway GO:0036462 8.8 CASP8 FADD TNFRSF10B
35 negative regulation of apoptotic process GO:0043066 10.01 EGFR ERBB2 HSP90B1 MCL1 PTEN VEGFA

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 BAX CASP8 CYP1A1 EGFR ERBB2 FADD
2 protein heterodimerization activity GO:0046982 9.63 BAX EGFR ERBB2 MCL1 TLR2 VEGFA
3 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 HSP90B1
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 EGFR ERBB2 PIK3CA
5 death receptor binding GO:0005123 9.46 CASP8 FADD
6 platelet-derived growth factor receptor binding GO:0005161 9.43 PTEN VEGFA
7 BH3 domain binding GO:0051434 9.32 BAX MCL1
8 death effector domain binding GO:0035877 9.26 CASP8 FADD
9 identical protein binding GO:0042802 9.23 BAX CASP8 EGFR ERBB2 FADD PTEN

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....